Article

Bactolife has secured over €30 million in its Series B funding round to launch its Binding Proteins aimed at promoting gut health by neutralizing harmful metabolites. The Danish biotech firm plans to enter the US market in 2026 and expand into Europe and Asia, with the investment supporting product launches, manufacturing scale-up, and clinical studies. Led by Cross Border Impact Ventures and EIFO, the funding will also facilitate the preparation of food safety dossiers for regulatory approval in the US and Europe.